Asset Details
Do you wish to reserve the book?
Lupus nephritis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Lupus nephritis
Do you wish to request the book?
Lupus nephritis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Lupus nephritis
2020
Overview
Lupus nephritis (LN) is a form of glomerulonephritis that constitutes one of the most severe organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE). Most patients with SLE who develop LN do so within 5 years of an SLE diagnosis and, in many cases, LN is the presenting manifestation resulting in the diagnosis of SLE. Understanding of the genetic and pathogenetic basis of LN has improved substantially over the past few decades. Treatment of LN usually involves immunosuppressive therapy, typically with mycophenolate mofetil or cyclophosphamide and with glucocorticoids, although these treatments are not uniformly effective. Despite increased knowledge of disease pathogenesis and improved treatment options, LN remains a substantial cause of morbidity and death among patients with SLE. Within 10 years of an initial SLE diagnosis, 5–20% of patients with LN develop end-stage kidney disease, and the multiple comorbidities associated with immunosuppressive treatment, including infections, osteoporosis and cardiovascular and reproductive effects, remain a concern. Clearly, early and accurate diagnosis of LN and prompt initiation of therapy are of vital importance to improve outcomes in patients with SLE.
Lupus nephritis is an inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus. This Primer reviews the epidemiology of lupus nephritis, its pathogenesis and advances in its treatment.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Calcineurin Inhibitors - therapeutic use
/ Cyclophosphamide - therapeutic use
/ Disease
/ Enzyme Inhibitors - therapeutic use
/ Humans
/ Immunosuppressive Agents - therapeutic use
/ Lupus
/ Lupus Erythematosus, Systemic - complications
/ Lupus Erythematosus, Systemic - physiopathology
/ Lupus Nephritis - physiopathology
/ Medicine
/ Mycophenolic Acid - therapeutic use
/ Plasma
/ Primer
